Khiron Life Sciences Corp.
Khiron Life Sciences Corp.
Your view on KHRNF
Overview
What the company does, where it operates, and who runs it.
About Khiron Life Sciences Corp.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Alvaro Francisco Torres
- Headquarters
- 500 Burrard Street, Vancouver, BC, CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Alvaro Francisco Torres
- Headquarters
- 500 Burrard Street, Vancouver, BC, CA
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis.
It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Khiron Life Sciences Corp., and the rating behind it. KHRNF last traded at $0.0000; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Khiron Life Sciences Corp.. Starting points for Khiron Life Sciences Corp.: EPS -$0.20, beta 5.75 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Khiron Life Sciences Corp.. Khiron Life Sciences Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Khiron Life Sciences Corp.. Trailing twelve-month EPS for Khiron Life Sciences Corp. stands at -$0.20. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Khiron Life Sciences Corp.. Khiron Life Sciences Corp. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Khiron Life Sciences Corp. valued side by side against its closest peers. Khiron Life Sciences Corp. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Khiron Life Sciences Corp., and how their positions are changing. At a $2,324 market value, institutional positions materially move Khiron Life Sciences Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Khiron Life Sciences Corp. executives and directors. Shares of Khiron Life Sciences Corp. have traded between $0.0000 and $0.0000 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Khiron Life Sciences Corp.. Khiron Life Sciences Corp. is a $2,324 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Khiron Life Sciences Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Khiron Life Sciences Corp.. Coverage tracks Khiron Life Sciences Corp. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.